Muse Cell Therapy for Back Pain: Current Evidence and Patient Questions
Medically reviewed by Dr. Charles Pereyra, MD — Medical Director, Springs Rejuvenation. Last reviewed October 15, 2026.
Written by the Springs Rejuvenation regenerative medicine team from direct clinical experience administering stem cell and exosome protocols at our Aventura, Miami center.
Back pain and spinal disc degeneration remain among the most common reasons patients seek regenerative medicine options. The intervertebral discs that cushion the spine lose hydration and structural integrity over time, a process driven by aging, mechanical stress, and the limited capacity of disc tissue to repair itself. When conservative approaches provide insufficient relief, some patients explore investigational cell-based therapies. Among these, Muse cell therapy for back pain in Miami and other centers represents an emerging area of research, though the clinical evidence for spinal applications remains in early stages.
Understanding Disc Degeneration and the Rationale for Cell Therapy
Intervertebral discs are composed of a fibrous outer ring and a gelatinous inner nucleus. These structures are poorly vascularized, meaning they receive limited blood flow and have a reduced capacity for self-repair compared to other tissues. As discs degenerate, they lose height, hydration, and biomechanical function, sometimes leading to nerve compression and chronic pain. The biological mechanisms involve inflammation, loss of proteoglycan content, and a decline in viable disc cells. Regenerative approaches aim to address these underlying cellular and biochemical deficits, though the pathways by which any cell therapy might support disc tissue remain investigational and incompletely understood.
What Are Muse Cells and How Do They Differ?
Multilineage-differentiating stress-enduring (Muse) cells are a distinct population of pluripotent-like cells first characterized by Kuroda, Dezawa, and colleagues in 2010. Unlike conventional mesenchymal stem cells, Muse cells are identified by the surface marker SSEA-3 and possess the ability to differentiate into cells from all three germ layers under certain conditions. Wakao, Dezawa, and colleagues (2011) demonstrated that Muse cells exist naturally in adult human tissues, including bone marrow and adipose tissue, and can be expanded without genetic manipulation. One defining feature is their tolerance to cellular stress—Muse cells survive conditions that eliminate other cell types, a characteristic that may be relevant in damaged or inflamed tissue environments like degenerated discs. However, translating these laboratory observations into clinical benefit for spinal conditions requires rigorous investigation that is still in progress.
Homing Mechanisms and Delivery Considerations
A central question in regenerative medicine is whether intravenously delivered cells can reach the target tissue. Yamada and colleagues (2018) identified a homing mechanism in which the sphingosine-1-phosphate (S1P) signaling pathway guides Muse cells to sites of tissue damage. In preclinical models, injured tissues release S1P, which interacts with the S1PR2 receptor on Muse cells, directing their migration to the affected area. This finding was published in the context of an acute injury model, and whether the same homing efficiency occurs in chronic degenerative spinal disease—where inflammation and signaling may differ—remains an open research question. The biology of disc degeneration is distinct from acute injury, and the microenvironment of a degenerated disc presents unique challenges for cell retention and function.
Published Safety Data and Gaps in the Evidence
Human safety trials for Muse cells have been conducted, though not specifically for back pain or spinal conditions. Noda and colleagues (2020) published the first-in-human safety study of CL2020, an intravenous Muse cell product, in a Japanese trial. The study documented the therapy's safety profile and provided preliminary data on feasibility, but the patient population and clinical endpoints were unrelated to musculoskeletal or spinal indications. Similarly, Niizuma and colleagues (2023) conducted a randomized, double-blind trial in Japan that further evaluated the product's safety and tolerability. The primary endpoints in that study were modest, illustrating an important principle: not every investigational therapy demonstrates robust efficacy even in well-designed trials, and individual responses vary widely. To date, no published randomized controlled trials have specifically examined Muse cells for disc degeneration or chronic back pain, leaving clinicians and patients to extrapolate cautiously from related research.
Hare and colleagues (2009) and Bartolucci and colleagues (2017) published randomized trials of intravenous allogeneic mesenchymal stem cells in other clinical contexts, establishing safety profiles for intravenous cell delivery but not addressing spinal applications directly. These studies contribute to the broader understanding of cell-based therapies but do not constitute direct evidence for back pain. The field of regenerative medicine for spinal conditions remains investigational, and patients considering Muse cell therapy for back pain in Miami or elsewhere should understand that the intervention is not FDA-approved for this indication and that outcomes cannot be predicted.
Physician Evaluation and Candidacy
Dr. Charles Pereyra, MD, emphasizes that candidacy for any investigational cell therapy begins with a comprehensive clinical assessment. Diagnostic imaging, neurological examination, and a detailed medical history inform whether a patient might be appropriate for participation in an investigational protocol. Not all patients with back pain are candidates, and some may have contraindications based on underlying health conditions. Physician-supervised evaluation ensures that patients understand the investigational nature of the therapy, the limited evidence base, and the realistic expectations for outcomes. Dr. Charles Pereyra and other physicians offering Muse cell therapy in the United States provide access to these investigational options without the need for patients to travel overseas, though the science supporting spinal applications is still evolving.
Current Limitations and the Path Forward
The published literature on Muse cells is promising in some respects but remains limited for back pain specifically. The mechanisms of disc degeneration are complex, and whether Muse cells can engraft, survive, and contribute to tissue repair in the low-oxygen, mechanically loaded environment of the spine is not yet established. Small studies and preclinical models suggest potential, but individual responses vary, and early-stage research does not always translate to clinical benefit. Patients exploring muse cell therapy for back pain in Miami should approach the decision with realistic expectations, recognizing that this is an investigational field with incomplete answers.
Frequently Asked Questions
How are Muse cells different from other stem cell therapies for back pain?
Muse cells are a distinct subset of pluripotent-like cells identified by the SSEA-3 marker and characterized by stress tolerance and the ability to differentiate into multiple cell types. Unlike conventional mesenchymal stem cells, Muse cells have demonstrated a homing mechanism mediated by the S1P–S1PR2 pathway in preclinical models. However, clinical evidence for spinal applications is limited, and the differences in outcomes between Muse cells and other cell types for back pain have not been established in randomized trials.
What does the published evidence show about Muse cell therapy for disc degeneration?
Published human trials of Muse cells, including first-in-human safety studies by Noda and colleagues (2020) and a randomized trial by Niizuma and colleagues (2023), have documented safety and feasibility but not in the context of spinal or musculoskeletal indications. No published randomized controlled trials have specifically evaluated Muse cells for disc degeneration or chronic back pain. The evidence remains early-stage, and outcomes are investigational.
Is Muse cell therapy for back pain FDA-approved?
No. Muse cell therapy is not FDA-approved for back pain, disc degeneration, or any musculoskeletal condition. Patients considering this investigational approach should understand that it is offered under research or physician-supervised protocols, and that efficacy has not been established through the FDA regulatory process. Individual responses vary, and no therapy has certain outcomes.
What should patients ask during a consultation for Muse cell therapy?
Patients should ask about the specific evidence supporting the therapy for their condition, the source and preparation of the cells, the delivery method, the monitoring plan, and realistic expectations for outcomes. Understanding candidacy criteria, potential risks, and the investigational nature of the approach is essential. Physician-led screening by providers like Dr. Charles Pereyra helps patients make informed decisions based on their individual clinical picture.
At Springs Rejuvenation, stem cell and exosome therapies are used together as part of a personalized regenerative protocol.
Medical Disclaimer: Stem cell and exosome therapy is not an FDA approved therapy and is considered to be in the experimental stages. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Springs Rejuvenation processes exosomes in an FDA approved lab. Individual results may vary. This content is reviewed for medical accuracy by Dr. Charles Pereyra, MD, Medical Director of Springs Rejuvenation, and is provided for educational purposes only. Always consult a qualified physician.